Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-retroviral efficacy, tolerance and other pharmacologic interactions of the non nucleoside analog efavirenz in association with rifampicin to treat tuberculosis and AIDS.

Next Previous
X
Search
Trial Profile

Anti-retroviral efficacy, tolerance and other pharmacologic interactions of the non nucleoside analog efavirenz in association with rifampicin to treat tuberculosis and AIDS.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efavirenz (Primary) ; Rifampicin
  • Indications HIV infections; Tuberculosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IPEC-EFV

    • Most Recent Events

    • 01 Oct 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 23 Jul 2010 Results in 63 patients reported at 18th International AIDS Conference.
    • 03 Nov 2008 Planned end date changed from 1 Sep 2008 to 1 Sep 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top